SOD1 and metabolic disease: Additionally, human clinical data on SOD enzymes or SOD mimetics in metabolic diseases remain scarce, and available interventions differ substantially in formulation, delivery method, and pharmacokinetic behavior, making it difficult to extrapolate or generalize findings.